Comparison · NCT01767194-deaths
Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): deaths from any cause. Trial comparisons, record NCT01767194-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01767194-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.437 | 0.837 | wilson | |
| Risk in group 2 | 0.294 | 0.187 | 0.43 | wilson | |
| Risk difference, group 1 minus group 2 | 0.373 | 0.106 | 0.574 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.27 | 1.33 | 3.87 | log | |
| Odds ratio, group 1 over group 2 | 4.8 | 1.52 | 15.2 | log | |
| Number needed to harm, for one more death from any cause on Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) than on Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab) | 2.68 | 1.74 | 9.42 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) | CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.~Irinotecan Hydrochloride: Given IV~Laboratory Biomarker Analysis: Optional correlative studies~Temozolomide: Given PO~Temsirolimus: Given IV | 12 | 18 | EG000 |
| Group 2 | Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab) | Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.~Dinutuximab: Given IV~Irinotecan Hydrochloride: Given IV~Laboratory Biomarker Analysis: Optional correlative studies~Sargramostim: Given SC or IV~Temozolomide: Given PO | 15 | 51 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Through completion of protocol therapy, up to approximately 1 year.
Source ClinicalTrials.gov
Trial
- Title
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
- NCT number
- NCT01767194
- Phases
- PHASE2
- Conditions
- Ganglioneuroblastoma, Recurrent Neuroblastoma
- Interventions
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Sargramostim, Temozolomide, Temsirolimus
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2019-11-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01767194?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01767194-deaths